Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) EPS (Weighted Average and Diluted) (2019 - 2025)

Theravance Biopharma (TBPH) has disclosed EPS (Weighted Average and Diluted) for 7 consecutive years, with $0.07 as the latest value for Q3 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 126.92% to $0.07 in Q3 2025 year-over-year; TTM through Sep 2025 was $0.54, a 153.47% increase, with the full-year FY2024 number at -$1.15, down 15.0% from a year prior.
  • EPS (Weighted Average and Diluted) was $0.07 for Q3 2025 at Theravance Biopharma, down from $1.08 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $1.08 in Q2 2025 to a low of -$1.35 in Q1 2021.
  • A 5-year average of -$0.27 and a median of -$0.27 in 2025 define the central range for EPS (Weighted Average and Diluted).
  • Peak YoY movement for EPS (Weighted Average and Diluted): tumbled 154.55% in 2023, then skyrocketed 417.65% in 2025.
  • Theravance Biopharma's EPS (Weighted Average and Diluted) stood at -$0.48 in 2021, then skyrocketed by 56.25% to -$0.21 in 2022, then grew by 19.05% to -$0.17 in 2023, then plummeted by 100.0% to -$0.34 in 2024, then skyrocketed by 120.59% to $0.07 in 2025.
  • Per Business Quant, the three most recent readings for TBPH's EPS (Weighted Average and Diluted) are $0.07 (Q3 2025), $1.08 (Q2 2025), and -$0.27 (Q1 2025).